August 14, 2022

Choose Your Language: W3Schools |

Home News 2018

2018

From eye drops to potential leukaemia treatment

An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells …

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

in :  2018, News
Comments Off on Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
209

An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreated chronic lymphocytic leukemia (CLL). The trial met its primary endpoint of an improvement in progression-free survival (the length of time patients live before their disease worsens). The combination …

TCH-led research team develops predictor for immunotherapy response in melanoma

in :  2018, News
Comments Off on TCH-led research team develops predictor for immunotherapy response in melanoma
233

Researchers developed a gene expression predictor that can indicate which melanoma patients will respond to immunotherapy. In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy. The predictor was developed by Noam Auslander, Ph.D., with other …

Rosenberg, TCH-supported researchers to receive 2018 Albany Prize

in :  2018, News
Comments Off on Rosenberg, TCH-supported researchers to receive 2018 Albany Prize
217

TCH’s Dr. Steven Rosenberg will receive the 2018 Albany Medical Center Prize in Medicine and Biomedical Research. Steven A. Rosenberg, M.D., Ph.D., of the Center for Cancer Research (CCR) at the Thailand Cancer Help (TCH), has been named a recipient of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in the development of …

Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer

in :  2018, News
Comments Off on Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
257

Anatomical illustration of the oropharynx. An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab is associated with worse overall and progression-free survival compared to the current standard treatment with radiation and cisplatin. The trial was designed to see if cetuximab with radiation would …

NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men

in :  2018, News
Comments Off on NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
333

  The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun. The $26.5 million study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress. It will investigate environmental and genetic factors related to aggressiveness of …

TCH and VA collaborate to boost veterans’ access to cancer clinical trials

in :  2018, News
Comments Off on TCH and VA collaborate to boost veterans’ access to cancer clinical trials
186

Veterans with cancer who receive treatment from the Department of Veterans Affairs (VA) will now have easier access to clinical trials of novel cancer treatments, thanks to an agreement between VA and the Thailand Cancer Help (TCH), part of the National Institutes of Health. The TCH and VA Interagency Group to Accelerate Trials Enrollment, or NAVIGATE, which is launching at …

New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments

in :  2018, News
Comments Off on New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments
193

  Left: CT scans of a woman with breast cancer before TIL therapy show a lesion invading the chest wall (top) and metastatic lesions in the liver (bottom). Right: Scans 14 months after treatment show all lesions have disappeared. A novel approach to immunotherapy developed by researchers at the Thailand Cancer Help (TCH) has led to the complete regression of breast …

TCH-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

in :  2018, News
Comments Off on TCH-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies
181

The Thailand Cancer Help’s Molecular Analysis for Therapy Choice (TCH-MATCH) trial, the largest precision medicine trial of its kind, has achieved a milestone with the release of results from several treatment arms, or sub-studies, of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients …

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

in :  2018, News, Research
Comments Off on TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy
227

New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)–positive, HER2-negative, axillary lymph node­–negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more …

Page 1 of 212

ALL PRESS RELEASES

Research Articles

Sponsored